AttenuationofHbA1creductionwasnotedinbothstudyarms at104weeks;however,thegradualincreaseinHbA1covertime was less profound with dapagliflozin than with glipizide. At week 208, dapagliflozin was associated with a reduced HbA1c concentration compared with glipizide (−0.10 vs 0.20%, respectively).